ArticleCancers2020
Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD,
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Familial melanoma: genetic, clinical, and dermoscopic insights and follow-up.Frontiers in medicine · 2026Review
- Germline Non-CDKN2A Variants in Melanoma and Associated Hereditary Cancer Syndromes.Diseases (Basel, Switzerland) · 2025Review
- Age-Related Variations in Clinical, Histological, and Genetic Characteristics in Multiple and Familial Melanomas: A Study of 333 Patients.Journal of clinical medicine · 2025Article
- How to Effectively Communicate Dismal Diagnoses in Dermatology and Venereology: From Skin Cancers to Sexually Transmitted Infections.Diagnostics (Basel, Switzerland) · 2025Review
- Bayesian analysis of the rate of spontaneous malignant mesothelioma among BAP1 mutant mice in the absence of asbestos exposure.Scientific reports · 2025Article
- Increased risk of skin cancers in mucous membrane pemphigoid: a large-scale matched cohort study of 117 million US individuals.Frontiers in medicine · 2025Article
- Polygenic Risk Score Improves Melanoma Risk Assessment in a Patient Cohort from the Veneto Region of Italy.Biology · 2024Article
- Prevalence of germline variants in Brazilian pancreatic carcinoma patients.Scientific reports · 2024Article
- Prevalence of CDKN2A, CDK4, POT1, BAP1, MITF, ATM, and TERT Pathogenic Variants in a Single-Center Retrospective Series of Patients With Melanoma and Personal or Family History Suggestive of Genetic Predisposition.Dermatology practical & conceptual · 2024Article
- Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting.International journal of molecular sciences · 2023Article
- Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma.International journal of molecular sciences · 2022Article
- Article
- Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup.ESMO open · 2022Article
- First international workshop of the ATM and cancer risk group (4-5 December 2019).Familial cancer · 2022Review
- Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients.Genes · 2021Article
- Review
- The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.Cancers · 2021Article
- Melanoma susceptibility: an update on genetic and epigenetic findings.International journal of molecular epidemiology and genetics · 2021Review
- Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 14 institutions in 2 countries.
Lorenza PastorinoGenetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genova, Italy.
Virginia AndreottiGenetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genova, Italy.
Bruna DalmassoGenetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genova, Italy.
Irene VanniGenetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genova, Italy.
Giulia CiccareseGenetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genova, Italy.
Mario MandalàUnit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy.
Giuseppe SpadolaDivisione di Chirurgia del Melanoma, IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori Milano, 20133, Italy.
Maria Antonietta PizzichettaDermatologic Clinic, University of Trieste, 34127 Trieste, Italy.
Giovanni PontiDepartment of Diagnostic and clinical medicine and public health, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Maria Grazia TibilettiDepartment of Pathology, ASST Sette Laghi, 21100 Varese, Italy.
Elena SalaMedical Genetics Laboratory, Clinical Pathology Department, S. Gerardo Hospital, 20900 Monza, Italy.
Maurizio GenuardiUOC Genetica Medica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Pietro ChiurazziUOC Genetica Medica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
Gabriele MaccantiUO Dermatologia P.O. Misericordia, 58100 Grosseto, Italy.
Siranoush ManoukianUnit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy.
Serena SestiniPlastic & Reconstructive Surgery Unit, Regional Melanoma Referral Center and Melanoma & Skin Cancer Unit Tuscan Tumour Institute (ITT), Santa Maria Annunziata Hospital, 50012 Firenze, Italy.
Rita DanesiRomagna Cancer Registry, IRCCS-IRST Scientific Institute of Romagna for the Study and Treatment of Cancer, 47014 Meldola, Italy.
Valentina ZampigaBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy.
Roberta La StarzaHematology and Bone Marrow Transplantation Unit, CREO, University of Perugia, 06156 Perugia, Italy.
Ignazio StanganelliSkin Cancer Unit, IRCCS-IRST Scientific Institute of Romagna for the Study and Treatment of Cancer, 47014 Meldola, Italy.
Alberto BallestreroIRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Luca MastracciIRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Federica GrilloIRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Stefania ScialleroIRCCS Ospedale Policlinico San Martino, Unit of Medical Oncology 1, 16132 Genova, Italy.
Federica CecchiIRCCS Ospedale Policlinico San Martino, Medical Oncology 2, 16132 Genova, Italy.
Enrica Teresa TandaIRCCS Ospedale Policlinico San Martino, Medical Oncology 2, 16132 Genova, Italy.
Francesco SpagnoloIRCCS Ospedale Policlinico San Martino, Medical Oncology 2, 16132 Genova, Italy.
Paola QueiroloIRCCS Ospedale Policlinico San Martino, Medical Oncology 2, 16132 Genova, Italy.
Italian Melanoma Intergroup (IMI)Italian Melanoma Intergroup (IMI), 16121 Genova, Italy.
Alisa M GoldsteinClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, MD 20892, USA.
William BrunoGenetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genova, Italy.
Paola GhiorzoGenetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genova, Italy.
Ospedale Policlinico San Martino · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITUniversità Cattolica del Sacro Cuore · ITAzienda Ospedaliera San Gerardo · ITAziende Socio Sanitarie Territoriale dei Sette LaghiItalian Institute of Technology · ITNational Cancer Institute · USOspedale Misericordia - Grosseto · ITOspedale Papa Giovanni XXIII · ITTumour Institute of Tuscany · ITUniversity of Modena and Reggio Emilia · ITUniversity of Perugia · ITUniversity of Trieste · IT
Funding
Family Studies ZIACP004410 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$56.1MAssociazione Italiana per la Ricerca sul Cancro IG 15480Ministero della Salute RF-2016-02362288
Abstract
The contribution of recently established or candidate susceptibility genes to melanoma missing heritability has yet to be determined. Multigene panel testing could increase diagnostic yield and better define the role of candidate genes. We characterized 273
Indexed as
ATMBAP1CDKN2Afamilial melanomagene panel sequencinggenetic susceptibilityhigh-penetrance genesmissing heritabilityPOT1variant interpretation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.